@spinogenix
A novel class of regenerative therapeutics to restore memory & motor function.
X
X
Instagram
Instagram
LinkedIn
LinkedIn
Spinogenix Announces FDA-Authorized Expanded Access Programfor SPG302, the First Synaptic Regenerative Therapy to Treat ALS - Spinogenix
Spinogenix Announces FDA-Authorized Expanded Access Programfor SPG302, the First Synaptic Regenerative Therapy to Treat ALS - Spinogenix
FDA Authorizes Expanded Access Program (EAP) to Help Provide Access to SPG302 for 200 ALS Individuals Ineligible for Clinical Study EAP Supports Real-world Data Collection Concurrent to Ongoing Clinical Studies of SPG302 LOS ANGELES – May 5, 2025 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives…
Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for Schizophrenia
Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for Schizophrenia
LOS ANGELES, CA, March 31, 2025 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced open enrollment for its Phase 2 trial of SPG302 for the treatment of people with schizophrenia, following clearance of its Investigational New Drug (IND) application by the…
Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity
Spinogenix Completes Phase 2 Study of SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism, Showing Strong Efficacy Signal in Measures of Abnormal Brain Activity
Topline Results Announced at NIH Fragile X Centers of Excellence Conference U.S. FDA Previously Granted Orphan Disease Designation and Fast Track Designation to SPG601 LOS ANGELES, Calif., February 11, 2025 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced topline results from a…
Spinogenix's SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome
Spinogenix's SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome
The company announced the completion of its phase 2 study assessing SPG601 in adult men with FXS, with topline findings expected to be reported by end of the first quarter in 2025.
FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism - Spinogenix
FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of Fragile X Syndrome, a Common Inherited Form of Autism - Spinogenix
Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors - Spinogenix
Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors - Spinogenix
LOS ANGELES, Calif., November 25, 2024—Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of people worldwide, today announced the appointment of Steve Young, hall of fame former quarterback of the San Francisco 49’ers and prominent health advocate, to its board of directors. Mr. Young brings his background…
Blog - Spinogenix
Blog - Spinogenix
pharmashots.com
pharmashots.com
Shots: With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease Today at PharmaShots,
To Reverse Aging’s Clock, Adjust the Cell’s Machinery
To Reverse Aging’s Clock, Adjust the Cell’s Machinery
Companies To Watch: Spinogenix
Companies To Watch: Spinogenix
Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board - Spinogenix
Spinogenix Announces Launch of Glaucoma Program and Addition of World-Renowned Expert Dr. Robert Weinreb to its Science Advisory Board - Spinogenix
Synapse-restoring pill set for human trials as novel schizophrenia treatment
Synapse-restoring pill set for human trials as novel schizophrenia treatment
Spinogenix, the company behind the once-a-day pill that restored lost nerve cell connections in people with amyotrophic lateral sclerosis (ALS), has now set its sights on using the pill to provide a novel treatment for another debilitating disease: schizophrenia.
First Synaptic Regenerative Therapy for Schizophrenia Under Investigation
First Synaptic Regenerative Therapy for Schizophrenia Under Investigation
Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.
Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia - Spinogenix
Spinogenix Announces Launch of a Phase 2 Clinical Trial Evaluating SPG302 for the Treatment of Schizophrenia - Spinogenix
Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia LOS ANGELES, Calif., September 25, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced that with the approval…
SPG601 for Restoring Synaptic Function in FXS
SPG601 for Restoring Synaptic Function in FXS
Channel 7 News Australia Feature
Channel 7 News Australia Feature
Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease - Spinogenix
Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease - Spinogenix
Blog - Spinogenix
Blog - Spinogenix
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome - Spinogenix
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome - Spinogenix
What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?
What are the Current Investment Trends in the Pharmaceutical Industry, and How are They Influencing the Sector’s Direction?
Synapse-regenerating drug could reverse decline in Alzheimer’s - Drug Discovery World (DDW)
Synapse-regenerating drug could reverse decline in Alzheimer’s - Drug Discovery World (DDW)
Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach - Spinogenix
Courage and Connections: Dan Doctoroff and Stella Sarraf Discuss ALS, Synapses, and Spinogenix’s Innovative Approach - Spinogenix
FDA grants orphan designation to Fragile X syndrome therapeutic
FDA grants orphan designation to Fragile X syndrome therapeutic
Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
MSN
MSN
The structure of an Amyloid Precursor Protein/talin complex indicates a mechanical basis of Alzheimer’s Disease
The structure of an Amyloid Precursor Protein/talin complex indicates a mechanical basis of Alzheimer’s Disease
ClinicalTrials.gov
ClinicalTrials.gov
Channel 9 News Australia "A Promising New Drug"
Channel 9 News Australia "A Promising New Drug"
SPG302 trial set to begin in Australia | MND Australia
SPG302 trial set to begin in Australia | MND Australia
Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials
Using EEG and TMS to capture treatment-related Brain Signals in Spinogenix Drug Trials
Actor Aaron Lazar opens up about ALS diagnosis
Actor Aaron Lazar opens up about ALS diagnosis
Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies
Investigating Auditory Electrophysiological Measures of Participants with Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Event-Related Potential Studies
onlinelibrary.wiley.com
onlinelibrary.wiley.com
Dysfunction of central control of breathing in amyotrophic lateral sclerosis - PubMed
Dysfunction of central control of breathing in amyotrophic lateral sclerosis - PubMed
SPG302 tested in a TAR4/4 ALS model by Dr. Justin Ichida at USC
SPG302 tested in a TAR4/4 ALS model by Dr. Justin Ichida at USC
6th Annual ALS ONE Research Symposium: Day 2 Industry Speaker: Peter Vanderklish, PhD of Spinogenix.
6th Annual ALS ONE Research Symposium: Day 2 Industry Speaker: Peter Vanderklish, PhD of Spinogenix.
SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease - Neurotherapeutics
SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease - Neurotherapeutics
An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD - Acta Neuropathologica
An interaction between synapsin and C9orf72 regulates excitatory synapses and is impaired in ALS/FTD - Acta Neuropathologica
Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS - Acta Neuropathologica
Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS - Acta Neuropathologica
Spinogenix Awarded Department of Defense Grant
Spinogenix Awarded Department of Defense Grant
Spinogenix Website
Spinogenix Website
Spinogenix Awarded $3 Million NIH Alzheimer's Grant
Spinogenix Awarded $3 Million NIH Alzheimer's Grant
View on mobile
Explore other Linktrees
whywontyoudateme
@whywontyoudateme
Best of Target
@BestofTarget
Kaitlyn Johnson
@missynjohnson
Keiko Lynn
@keikolynn
Stanley Tucci
@stanleytucci
Dua Lipa
@dua.lipa
Fibs and Friends
@fibsandfriends
Tate McRae
@tatemcrae
Autym
@autym
Deuxmoi
@deuxmoi
previous
next
Discover more
See all
@jhuker_gyn
@zpqszsfxpt
@jacqueline.lfa
@cantileverinteriors
@sente_o_coracao
@CGMacedo
@kittycandy
@Crowningmidwifery
@mercado.equilibrio
@inhousew
@boto_shopping
@thebathroomsandtiles
@apoteksamfarma
@jmproducoeseeventos
@eyelashextensionlstudio
@x_a1sinceday1
@embassymetrodetroit
@bambooblondeindo
@merytarigan09
@Capitasdeamor
@loquidy.schoolcup
@NVDProduction
@sr12graharaya
@SAMAgency_99
@Abodiba
@outdoorlivingandwellnessexpo
@kenjy_mzd
@cgueutm
@SmokeyVisions
@sallynncolorado
@Thehockeybaby
@glenncase
@AnthonyQTM
@vermudezmichel29
@Joujou19
@etelinktree
@agathapublicidad
@JNbusiness97
@cryexofficial
@EZIA
@studioberrakyurdakul
@palaciolibertad
@smhsohan
@BMFITNESS_GYM
@goldenhour_tw
More from Linktree
Products
Link in bio + tools
Manage your social media
Grow and engage your audience
Monetize your following
Measure your success
Templates
Marketplace
Learn
Resources
How to use Linktree
Pricing
Link in bio + tools
Link in bio
Customize your Linktree
Link shortener
Create trackable, shareable short links
QR code generator
Turn links into scannable QR codes
Canva Background Editor
Import your custom designs from Canva into your profile
Linktree for every social platform
Grow and engage your audience everywhere
Instagram
TikTok
LinkedIn
X
Manage your social media
Schedule and auto-post
Hands-free, hassle-free social media planning
Instagram auto reply
Automated replies and DMs triggered by comments
AI content & caption generator
Instant AI-powered post ideas and captions
Hashtag generator
Trending hashtag suggestions for better reach
Social integration for every social platform
Plan, auto post, and share across all platforms
Instagram
TikTok
Facebook
Pinterest
LinkedIn
Threads
Youtube
Grow and engage your audience
Collect leads with contact forms
Turn visitors into subscribers
Manage and activate your audience
Organize, tag, and track contacts
Send contacts to email tools
Sync with Mailchimp, Klaviyo, Kit & more
Monetize your following
Earn with a Linktree Shop
Sell products and earn commission
Sell an online course
Create and sell your expertise easily
Host digital products
Sell digital products and build your email list
Earn by hosting sponsored links
Share brand offers and earn for every sign-up or sale
Get rewarded for growing your Linktree
Earn points, level up and unlock cash bonuses
Booked and paid, easily
Offer sessions and earn from your expertise
Measure your success
Social + link analytics
Track clicks, engagement and audience insights
Resources
Read our blog
All the latest tips, tricks and growth strategies
Success Stories
Real people, real results on Linktree
How to use Linktree
Linktree Help Centre
Get answers, guides and support
×
Advertisement